AFIB (Acutus Medical) Debt-to-Equity: -3.09 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Acutus Medical Debt-to-Equity?

Acutus Medical AFIB Debt-to-Equity is -3.09 as of Dec. 2024.

Acutus Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $7.96 Mil. Acutus Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $27.80 Mil. Acutus Medical's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-11.59 Mil. Acutus Medical's debt to equity for the quarter that ended in Dec. 2024 was -3.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Acutus Medical's Debt-to-Equity or its related term are showing as below:

AFIB's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Acutus Medical  (OTCPK:AFIB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Acutus Medical Debt-to-Equity Related Terms

Acutus Medical Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Acutus Medical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acutus Medical Debt-to-Equity Chart

Acutus Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial 0.33 0.43 0.52 -43.78 -3.09

Acutus Medical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.78 -9.57 -7.46 -3.47 -3.09

AFIB vs DHAI, ABT, BSX: Debt-to-Equity Comparison

For the Medical Devices subindustry, Acutus Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acutus Medical Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Acutus Medical's Debt-to-Equity falls into.


Acutus Medical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Acutus Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(7.962 + 27.802) / -11.592
=-3.09

Acutus Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(7.962 + 27.802) / -11.592
=-3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -3.09 mean?
Acutus Medical (AFIB) has a Debt-to-Equity of -3.09 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Acutus Medical and its competitors.
Is Acutus Medical's Debt-to-Equity too high?
Acutus Medical's current Debt-to-Equity is -3.09.
How does Acutus Medical's Debt-to-Equity compare to DHAI and ABT?
Acutus Medical's Debt-to-Equity of -3.09 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Acutus Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acutus Medical's current Debt-to-Equity is -3.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acutus Medical stock overvalued right now?
Acutus Medical (AFIB) has a current Debt-to-Equity of -3.09. The current Debt-to-Equity is -3.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Acutus Medical (AFIB), the current Debt-to-Equity is -3.09 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acutus Medical Business Description

Address 2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping, and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products world-wide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Outside the United States.